Standout of the week
I
Innatrix
Durham agricultural biotechnology company
NSF awards $499,786 to advance InnaLB toward registration.
The Phase IIB supplement supports work on Innatrix’s late-blight peptide, including formulation, manufacturing and safety studies ahead of EPA registration. NCBiotech reports $1,702,087 in cumulative NSF funding for this project, with its performance period extended through September 2027. The company’s stated $2 million seed raise is a fundraising target, not a completed round.
North Carolina Biotechnology Center·Aug 27
Deep dives
Capital
0 rounds
The capital figure is Innatrix’s NSF award. Higgs Boson Health’s acquisition price was not disclosed.